公开(公告)号：US12059497B2

公开(公告)日：2024-08-13

申请号：US17208042

申请日：2021-03-22

Applicant: Ipsen Biopharm Ltd.

Inventor： Daryl C. Drummond ,  Dmitri B. Kirpotin ,  Mark E Hayes ,  Charles Noble ,  Kevin Kesper ,  Antoine M. Awad ,  Douglas J. Moore ,  Andrew J. O'Brien

IPC: A61K9/127 ,  A61K31/4745

CPC classification number: A61K9/1271 ,  A61K9/1277 ,  A61K31/4745 ,  Y10S977/773 ,  Y10S977/906 ,  Y10S977/907

Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.

公开(公告)号：US20190161350A1

公开(公告)日：2019-05-30

申请号：US16092130

申请日：2017-04-07

Applicant: MOLECULAR REBAR DESIGN, LLC

Inventor： Kurt W. Swogger ,  Clive P. Bosnyak ,  Nancy Henderson ,  Malcolm Finlayson ,  Bryce Daniel Sturtevant ,  Steve Hoenig

IPC: C01B32/168 ,  C08K3/04 ,  C02F1/28 ,  C08K7/24 ,  C01B32/16

CPC classification number: C01B32/168 ,  A61K9/0019 ,  A61K9/0092 ,  A61K47/02 ,  A61L27/08 ,  A61L27/3675 ,  A61L27/3804 ,  A61P25/28 ,  B82Y5/00 ,  B82Y30/00 ,  B82Y35/00 ,  B82Y40/00 ,  C01B32/16 ,  C01B32/174 ,  C01B32/178 ,  C01B2202/06 ,  C01B2202/34 ,  C01B2202/36 ,  C02F1/283 ,  C02F2101/30 ,  C02F2101/36 ,  C02F2103/06 ,  C02F2305/08 ,  C08K3/04 ,  C08K7/24 ,  C12N5/0623 ,  Y10S977/744 ,  Y10S977/748 ,  Y10S977/752 ,  Y10S977/846 ,  Y10S977/847 ,  Y10S977/903 ,  Y10S977/906

Abstract: Discrete, individualized carbon nanotubes having targeted, or selective, oxidation levels and/or content on the interior and exterior of the tube walls are claimed. Such carbon nanotubes can have little to no inner tube surface oxidation, or differing amounts and/or types of oxidation between the tubes' inner and outer surfaces. These new discrete carbon nanotubes are useful in plasticizers, which can then be used as an additive in compounding and formulation of elastomeric, thermoplastic and thermoset composite for improvement of mechanical, electrical and thermal properties.

公开(公告)号：US20180221281A1

公开(公告)日：2018-08-09

申请号：US15872895

申请日：2018-01-16

Applicant: AKINA, INC.

Inventor： Kinam Park ,  Ghanashyam S. Acharya ,  Haesun Park

IPC: A61K9/16 ,  A61K9/50 ,  A61K31/00

CPC classification number: A61K9/1682 ,  A61K9/1647 ,  A61K9/5031 ,  A61K9/5089 ,  A61K31/00 ,  Y10S977/773 ,  Y10S977/887 ,  Y10S977/89 ,  Y10S977/906

Abstract: Discrete microstructures of predefined size and shape are prepared using sol-gel phase-reversible hydrogel templates. An aqueous solution of hydrogel-forming material is covered onto a microfabricated silicon wafer master template having predefined microfeatures, such as pillars. A hydrogel template is formed, usually by lowering the temperature, and the formed hydrogel template is peeled away from the silicon master template. The wells of predefined size and shape on the hydrogel template are filled with a solution or a paste of a water-insoluble polymer, and the solvent is removed to form solid structures. The formed microstructures are released from the hydrogel template by simply melting the hydrogel template in water. The microstructures are collected by centrifugation. The microstructures fabricated by this method exhibit pre-defined size and shape that exactly correspond to the microwells of the hydrogel template. The method of preparing microstructures based on hydrogel templates is simple and can easily produce large quantities of the microstructures.

公开(公告)号：US10004764B2

公开(公告)日：2018-06-26

申请号：US15034700

申请日：2014-11-06

Applicant: University of Pittsburgh—Of the Commonwealth System of Higher Education

Inventor： Janet S. Lee ,  Timothy E. Corcoran ,  Valerian Kagan

IPC: A61K9/127 ,  A61K35/18 ,  A61K9/00 ,  A61K9/14 ,  A61K35/12

CPC classification number: A61K35/18 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/127 ,  A61K9/14 ,  A61K2035/124 ,  Y10S977/773 ,  Y10S977/906 ,  Y10S977/907

Abstract: Cell-based therapies show considerable potential as an immunomodulatory strategy for a variety of lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, bronchiolitis, acute lung injury, lung allograft rejection (acute or chronic), pulmonary fibrosis. Described herein is the development of red blood cell membrane-derived microparticles (RBC MPs), which are depleted of hemoglobin (Hb) and express phosphatidylserine on their surface, for the treatment of lung disease. Administration of RBC MPs to the lung via inhalation promotes the production of immunoregulatory cytokines (such as IL-10), and reduces inflammation and injury in the lung.

公开(公告)号：US09987367B2

公开(公告)日：2018-06-05

申请号：US14426353

申请日：2013-09-06

Applicant: NANYANG TECHNOLOGICAL UNIVERSITY

Inventor： Subramanian Venkatraman ,  Tina Tzee Ling Howden ,  Leonardus Kresna Widjaja

IPC: A61K47/36 ,  A61K9/16 ,  A61K9/127 ,  A61K31/5575 ,  A61K31/7105 ,  A61K31/513 ,  A61K9/00 ,  A61K9/06 ,  A61K31/216 ,  A61K31/728 ,  A61K9/51

CPC classification number: A61K47/36 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/127 ,  A61K9/1647 ,  A61K9/5161 ,  A61K31/216 ,  A61K31/513 ,  A61K31/5575 ,  A61K31/7105 ,  A61K31/728 ,  Y10S977/773 ,  Y10S977/906 ,  Y10S977/907

Abstract: The present invention relates to novel hyaluronic acid (HA) hydrogels comprising vesicles loaded with a drug or a protein or a nucleic acid. The new HA hydrogels provide sustain release formulations that are useful for several clinical and surgical applications, including but not limited to ophthalmology (e.g. glaucoma, corneal, ocular inflammatory, vitreoretinal and medical retinal diseases) and dermatological conditions.

公开(公告)号：US20180037459A1

公开(公告)日：2018-02-08

申请号：US15730284

申请日：2017-10-11

Applicant: MOLECULAR REBAR DESIGN, LLC

Inventor： Kurt W. Swogger ,  Clive P. Bosnyak ,  Nancy Henderson ,  Malcolm Finlayson ,  Bryce Sturtevant ,  Steve Hoenig

IPC: C01B32/174 ,  A61K47/52 ,  H01F1/42 ,  C08K9/02 ,  C08K7/24 ,  C08K3/04 ,  A61K47/69 ,  A61K31/455

CPC classification number: C01B32/174 ,  A61K9/0092 ,  A61K31/455 ,  A61K47/52 ,  A61K47/6923 ,  B82Y5/00 ,  B82Y25/00 ,  B82Y30/00 ,  B82Y40/00 ,  C01B32/168 ,  C01B32/178 ,  C01B2202/06 ,  C01B2202/34 ,  C01B2202/36 ,  C02F1/283 ,  C02F2101/30 ,  C02F2101/36 ,  C02F2103/06 ,  C02F2305/08 ,  C08K3/041 ,  C08K7/24 ,  C08K9/02 ,  C08K2201/011 ,  H01F1/42 ,  Y10S977/744 ,  Y10S977/746 ,  Y10S977/748 ,  Y10S977/752 ,  Y10S977/753 ,  Y10S977/846 ,  Y10S977/847 ,  Y10S977/903 ,  Y10S977/906 ,  Y10S977/962

Abstract: Discrete, individualized carbon nanotubes having targeted, or selective, oxidation levels and/or content on the interior and exterior of the tube walls are claimed. Such carbon nanotubes can have little to no inner tube surface oxidation, or differing amounts and/or types of oxidation between the tubes' inner and outer surfaces. These new discrete carbon nanotubes are useful in plasticizers, which can then be used as an additive in compounding and formulation of elastomeric, thermoplastic and thermoset composite for improvement of mechanical, electrical and thermal properties.

公开(公告)号：US20180028444A1

公开(公告)日：2018-02-01

申请号：US15550786

申请日：2016-02-12

Applicant: OP NANO CO., LTD. ,  TRENDMED CO., LTD.

Inventor： Chi-Mu Chuang ,  Chi-Tai Chang

IPC: A61K9/127 ,  A61K47/34 ,  A61K9/107 ,  A61K31/337 ,  A61K9/00

CPC classification number: A61K9/127 ,  A61K9/0019 ,  A61K9/1075 ,  A61K31/337 ,  A61K47/34 ,  A61P35/00 ,  Y10S977/773 ,  Y10S977/906 ,  Y10S977/907

Abstract: The present invention is directed to a method for treating cancer intraperitoneally in a subject. The method comprises administering to said subject in need thereof an anti-cancer agent encapsulated in nanoparticles wherein nanoparticles are characterized to slowly release anti-cancer agent in a timely fashion that allows efficient killing of tumor cells. The nanoparticles described herein are characterized to slowly release anti-cancer agent at a rate of 30% or less per 24 hours based on in vitro drug dissolution study.

公开(公告)号：US20170340624A1

公开(公告)日：2017-11-30

申请号：US15664976

申请日：2017-07-31

Applicant: Ipsen Biopharm Ltd.

Inventor： Keelung Hong ,  Daryl C. Drummond ,  Dmitri Kirpotin

IPC: A61K31/4745 ,  A61K47/60 ,  A61K9/00 ,  A61K9/127 ,  A61K47/28 ,  A61K47/24 ,  A61K47/10 ,  A61K31/704 ,  A61K47/69 ,  A61K31/4375 ,  A61K31/337 ,  A61K31/475 ,  A61K47/26 ,  C07H13/12

CPC classification number: A61K31/4745 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/1271 ,  A61K9/1277 ,  A61K9/1278 ,  A61K31/337 ,  A61K31/4375 ,  A61K31/475 ,  A61K31/704 ,  A61K47/10 ,  A61K47/24 ,  A61K47/26 ,  A61K47/28 ,  A61K47/60 ,  A61K47/6913 ,  C07H13/12 ,  Y10S977/773 ,  Y10S977/906 ,  Y10S977/907

Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

公开(公告)号：US20170319573A1

公开(公告)日：2017-11-09

申请号：US15661868

申请日：2017-07-27

Applicant: Ipsen Biopharm Ltd.

Inventor： Daryl C. Drummond ,  Dmitri B. Kirpotin ,  Mark Eamon Hayes ,  Charles Noble ,  Kevin Kesper ,  Antoine M. Awad ,  Douglas J. Moore ,  Andrew J. O'Brien

IPC: A61K31/4745 ,  A61K47/02 ,  A61K9/127

CPC classification number: A61K31/4745 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/1271 ,  A61K9/1277 ,  A61K9/1278 ,  A61K47/02 ,  Y10S977/773 ,  Y10S977/906 ,  Y10S977/907

Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.

公开(公告)号：US20170319507A1

公开(公告)日：2017-11-09

申请号：US15649768

申请日：2017-07-14

Applicant: San Heh Pharmaceutical Corporation

Inventor： Weiwei GAO ,  Yu-Chen Chen

IPC: A61K9/51 ,  A61K9/107 ,  A61K31/43

CPC classification number: A61K9/5192 ,  A61K9/1075 ,  A61K9/5123 ,  A61K9/5161 ,  A61K31/43 ,  A61K31/722 ,  Y02A50/473 ,  Y02A50/481 ,  Y10S977/773 ,  Y10S977/896 ,  Y10S977/906 ,  A61K2300/00

Abstract: The present invention provides a process for preparing the nanoparticles. The process comprises first forming a water-in-oil emulsion from chitosan lactate, amoxicillin, dioctyl sodium sulfosuccinate, glutaraldehyde or bis[sulfosuccinimidyl] suberate, and oil, and sonicating the mixture of to form nanoparticles comprising chitosan crosslinked by dioctyl sodium sulfosuccinate and glutaraldehyde or by dioctyl sodium sulfosuccinate and bis[sulfosuccinimidyl] suberate, wherein the nanoparticles have an average diameter of 100-600 nm and have amoxicillin entrapped by the crosslinked chitosan. The present invention is also directed to nanoparticles comprising crosslinked chitosan and amoxicillin, wherein amoxicillin is entrapped by the crosslinked chitosan. The nanoparticles have an average diameter of 100-600 nm, and the entrapped amoxicillin is at least 5% (w/w) of the total weight nanoparticles.